Recent changes
Method to Change Tumor Associated Macrophage Polarization Using Magnetosomes and Radiation
USPTO published patent application US20260097075A1 by Université Paris Cité for a method to change tumor-associated macrophage polarization by exposing macrophages to magnetosomes and radiation. The invention aims to shift macrophages from M0 or Mi polarization to Mj polarization for potential cancer immunotherapy applications.
Modified Gamma Delta T Cells for Cancer Therapy
USPTO published patent application US20260097077A1 for a method of treating cancer using gamma delta T cells modified with XBP1 gene or protein inhibitors. The modified T cells demonstrate enhanced antitumor activity in tumor microenvironments with endoplasmic reticulum stress. Inventors are Minkyung Song, Hocheol Shin, and Ji Yun Park, with application filed September 4, 2025.
Cell Behavior Control Methods Without Genetic Modification
USPTO published patent application US20260097078A1 by inventors Victor TETS and Georgy TETS covering products and methods for managing cell behavior, cell memory, and erasure of cell memory without genetic modification. The application relates to therapeutic, diagnostic, agricultural, and biomanufacturing applications. The invention distinguishes itself from prior art by enabling control of cellular properties without mutagens, gene introduction, or environmental condition changes.
Removing Endogenous TCR Chains for Enhanced TCR-Based Immunotherapies
USPTO published patent application US20260097079A1 by Khosravi Maharlooei et al. disclosing methods for treating diseases using adoptive cell therapy with modified lymphocytes having inactivated endogenous TCRα and TCRβ chains. The application covers compositions and methods for enhanced TCR-based immunotherapies.
Exosomes from Mesenchymal Stem Cells for Alzheimer's Treatment
USPTO published patent application US20260097080A1 covering exosomes isolated from mesenchymal stem cells for reducing inflammation and treating Alzheimer's disease. The application claims exosomes exposed to conditioned media with microglial cells in the presence of LPS or beta-amyloid oligomer. This is a publication of a pending application, not a granted patent.
Human Hair Follicle-Derived Conditioned Media and Method of Making Same
USPTO published patent application US20260097082A1 covering methods for preparing hair follicle-derived conditioned media containing bioactive factors. The hair follicles are retrieved non-invasively and cultured to secrete therapeutic compounds. The application covers compositions for therapeutic and cosmetic treatments including hair restoration and skin repair.
PTGS2 Skin Disorders Carnosine Compound Treatment Method
USPTO published patent application US20260096978A1 disclosing a method for preventing, mitigating, or treating PTGS2-induced skin disorders using carnosine compounds of formula (I) applied to human skin. The application, filed November 14, 2022, names five inventors and covers cosmetic and dermatological formulations.
Ammonium Chloride Formulations for Viral Defense
The USPTO published patent application US20260097072A1 for ammonium chloride formulations designed to support human natural defense against viral infections. The invention claims compositions and methods using lysosomotropic agents, such as ammonium chloride (NH4Cl), to prevent viral uncoating within lysosomes of infected cells. The patent names Nikolaos Tsirikos-Karapanos and Nikolaos Drakoulis as inventors.
Engineered Immune Cells CAR-T CAR-NK BCMA TACI Cancer Therapy Patent Application
USPTO published patent application US20260097076A1 for engineered immune cells (T cells and NK cells) expressing chimeric antigen receptors targeting BCMA and/or TACI antigens for cancer therapy. The application discloses armored CAR-T and CAR-NK cells with enhanced features for tumor treatment. Filed September 20, 2023, by inventors Chen, Agrahari, Zhao, Nguyen, Zhang, Jiang, and O'Callaghan.
Pharmaceutical Composition Containing Neonatal Pig-Derived Mesenchymal Stem Cells for Treating Non-Porcine Animals
USPTO published patent application US20260097081A1 by Fukuoka University for a pharmaceutical composition containing neonatal pig-derived mesenchymal stem cells. The cells produce at least one humoral factor selected from TGF-β1, TGF-β2, VEGF-A, and VEGF-C for therapeutic use in treating cardiovascular conditions, wounds, and decubitus in non-porcine animals. The application was filed on October 10, 2025.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
697 changes in last 7 days
Latest high priority updates
141 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.